Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade
Authors:
- 16 March 2023
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 41 (4) , 651-652
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Yale School of Medicine
- National Cancer Institute (F30CA250249)
- National Cancer Institute (T32GM136651)
This publication has 9 references indexed in Scilit:
- Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial CarcinomaCancer Discovery, 2022
- In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancerNature Immunology, 2022
- The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screensImmuno-Oncology and Technology, 2021
- Disease variant prediction with deep generative models of evolutionary dataNature, 2021
- Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cellsNature Communications, 2020
- Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint BlockadeCell, 2019
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsCancer Discovery, 2017
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 TherapyCell, 2016
- Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaNew England Journal of Medicine, 2016